

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A method for increasing ~~blood-platelet formation count~~ in a patient in need of said ~~therapy thereof~~, comprising

administering to said patient an effective amount of ~~a composition comprising for said therapy of, as active ingredient, a parathyroid hormone (PTH) or at least one PTH a derivative thereof. effective for said therapy,~~

~~wherein said PTH or PTH derivative is selected from groups (a) to (c):~~

- ~~(1) a PTH derivative which comprises PTH(1-34), the constituent amino acid(s) of which may be substituted in the 8 position, 16 position and/or 34 position,~~
- ~~(2) a PTH derivative which is such that one or more of the constituent amino acids of PTH(1-34), the constituent amino acid residue(s) of which may be substituted in the 8 position, 16 position and/or 34 position, are deleted, and~~
- ~~(3) PTH or a PTH derivative selected from the group consisting of human PTH(1-34), human PTH(1-34)-~~

~~NH<sub>2</sub>-human PTH(1-37), human PTH(1-64), human  
PTH(1-84), human PTH(35-84) and bovine PTH(1-  
34).~~

2. (currently amended) The method according to claim 1 wherein said PTH or PTH derivative modified with polyethylene glycol is administered ~~along with polyethylene glycol~~.

3. (original) The method according to claim 1 wherein said PTH or PTH derivative is administered encapsulated within microcapsules.

4. (currently amended) The method according to claim 1 wherein said PTH or PTH derivative is ~~administered in a form~~ incorporated in a sheet of gel.

5. (original) The method according to claim 1 wherein said patient is a patient suffering from thrombocytopenia purpura.

6. (currently amended) The method according to claim 1 wherein said patient is ~~one~~ a patient suffering from selective suppression of megakaryocytes.

7. (original) The method according to claim 6 wherein said patient is a patient who has been or is being

treated with at least one of phenylbutazone, gold compounds, tolbutamide and chemotherapeutics.

8. (currently amended) The method according to claim 1 wherein said patient is ~~one~~-a patient suffering from a viral infection.

9. (currently amended) The method according to claim 1 wherein said patient is ~~one~~-a patient suffering from aplastic anemia.

10. (currently amended) The method according to claim 1 wherein said patient is ~~one~~-a patient suffering from osteomyelodysplasia syndrome.

11. (currently amended) The method according to claim 1 wherein said patient is ~~one~~-a patient suffering from leukemia.

12. (currently amended) The method according to claim 1 wherein said patient is ~~one~~-a patient suffering from multiple myeloma.

13. (original) The method of claim 1 wherein said PTH or PTH derivative is selected from the group consisting of human PTH (1-34), human PTH (1-64), human PTH (35-84), bovine

PTH (1-34), human PTH (1-84), human PTH (1-38) and human PTH (1-37).

14. (original) The method of claim 13 wherein said PTH or said PTH derivative has at least one of the following substitutions: (1) substitution of leucine or norleucine at the 8-position, (2) substitution of leucine or norleucine at the 18-position, and (3) substitution to tyrosine at the 34-position.

15. (currently amended) The method according to claim 1 wherein said effective amount is in the range of 1  $\mu$ g to 1,000  $\mu$ g per kg of body weight administered systemically at a frequency ranging from once per day to once per month.

16. (currently amended) The method according to claim 1 wherein said effective amount is from 5  $\mu$ g to 200  $\mu$ g per kg of body weight administered from once every two weeks to once daily.

17. (original) The method according to claim 1 wherein the route of said administration is subcutaneously.

18. (original) The method according to claim 1 wherein the route of said administration is intravenously.

19. (original) The method according to claim 1 wherein the route of said administration is intranasally.

20. (original) The method according to claim 1 wherein the route of said administration is transpulmonarily.

21. (new) The method of claim 13, wherein said PTH or PTH derivative is human PTH (1-34).